EDDA Health Announces $150 Million Strategic Financing to Advance Intelligent Surgical Robotics and Precision Surgery Solutions

VCBeat (WeChat ID: vcbeat) has learned that EDDA Healthcare and Technology Holding Ltd., an innovator in intelligent surgical robots and comprehensive precision surgery solutions, along with its subsidiaries Yiruan Information Technology (Shanghai) Co., Ltd., Yida Jixing Medical Technology (Suzhou) Co., Ltd., and EDDA Technology, Inc. (Princeton, USA) (collectively referred to as “EDDA Technology”), announced today the completion of a $150 million financing round. The investment was led by SoftBank Vision Fund 2*, with participation from renowned healthcare industry fund OrbiMed and 3W Fund. Previous investors in the company include Morningside Venture Capital, Matrix Partners China, SoftBank China, BOC Investment, Trustbridge Partners, and DCD Innovation, among other prominent funds.

EDDA HealthTech is a pioneer and leader in the fields of intelligent surgical robots and comprehensive solutions for intelligent precision surgery. It innovates, expands, and leads the market both domestically and internationally. Its proprietary core technology platform empowers a series of products and services, with intelligent surgical robots at the core, providing doctors with holistic solutions for precision surgery. Its products and services have been implemented in hundreds of hospitals and departments worldwide, including the Mayo Clinic in the United States, Peking Union Medical College Hospital, West China Hospital of Sichuan University, and Ruijin Hospital in Shanghai.

In the field of intelligent surgical robots, the company obtained China’s first NMPA Class III medical device registration certificate in 2020 for applications involving all thoracic and abdominal soft-tissue organs, qualifying for the national-level “Green Channel” for innovative medical devices. The product was evaluated as having significant clinical value by improving puncture accuracy and reducing the number of needle insertions and CT scans compared with conventional CT-guided methods. This product has entered the market promotion stage and has been successfully implemented in clinical practice.

This round of funding will be primarily used to strengthen the development of the company’s products under research, promote the marketing and commercialization of existing product lines, and advance strategic cooperation planning, thereby comprehensively building a precision surgery technology platform centered on intelligent cloud services and intelligent surgical robots, empowering physicians to better serve patients.

Dr. Jianzhong Qian, Chairman and CEO of EDDA Technology, Fellow of the American Institute for Medical and Biological Engineering (AIMBE)He stated, “Surgery has entered a new era characterized by precision. EDDA Technology’s IQQA® intelligent surgical robot has emerged at the right time, overcoming the critical limitations of traditional robotic surgery—namely, the lack of ‘intelligence’ and ‘visualization’—thereby bringing artificial intelligence into the operating room, empowering the precision surgery health ecosystem, and seizing a prime opportunity for development. The investment in EDDA Technology by professional investment funds with exceptional strategic vision and market insight, including SoftBank Vision Fund 2, OrbiMed, and 3W Capital, will further promote the company’s continuous leadership in precision surgical technology innovation during this new phase of growth. It will enable the company to tap into the vast market for next-generation intelligent surgical robots, effectively extend its reach to empower secondary and tertiary city-level grassroots hospitals, and make greater contributions to the diagnosis and treatment of major diseases such as cancer.”

Xu Juan, Partner at SoftBank Vision Fund 2stated: “We firmly believe that as an innovative leader in medical technology, EDDA Technology can deliver greater clinical value by integrating precision surgery with AI and robotics. We look forward to deepening our collaboration with Dr. Jianzhong Qian and the EDDA team to support EDDA Technology’s mission of improving treatment outcomes for patients in China and around the world through advanced technologies.”

Ms. Wang Ting, Partner at OrbiMedstated: “EDDA Technology’s intelligent surgical robot products can customize personalized, precise surgical plans, significantly improving the accuracy of surgical procedures and mitigating surgical risks. We believe that the visionary management team at EDDA will successfully achieve commercialization of its products, and we look forward to EDDA Technology continuing to advance the development of AI-driven surgical robots in the field of surgery, addressing unmet medical needs and benefiting more patients worldwide.”

Ms. Chen Siyu, Managing Director of 3W Fundstated: “As a pioneering innovator in intelligent surgical robots and precision surgery application solutions, EDDA Technology has cultivated deep expertise in the industry for many years, providing physicians with comprehensive, integrated services spanning diagnosis, treatment, and care. Meanwhile, it has successfully achieved product registration in both China and the United States. We believe that under the leadership of Dr. Jianzhong Qian and his team, EDDA Technology will continue to leverage its leading technological advantages and extensive clinical operational experience to successfully commercialize its products and empower healthcare with AI.”

*As of the date of this press release, SoftBank Group has made capital contributions and permitted SoftBank Vision Fund 2 to invest in certain portfolio companies. The information contained herein is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any limited partnership interests in any fund (including SoftBank Vision Fund 2). SoftBank Vision Fund 2 has not yet completed its external fundraising, and third-party investors will receive additional information regarding the investment projects of SoftBank Vision Fund 2 prior to the completion of such fundraising.

EDDA Technology has been dedicated to precision medicine for over a decade, leveraging its proprietary, independently developed intellectual property rights in IQQA^®Hardcore Technology Platform, Empowering the Creation of Intelligent Surgical Robots and Their Precision Surgery Health Ecosystem, Has Obtained Multiple International Certifications Including China NMPA and US FDA. From Innovative Technology to Empowering Platform to Health Ecosystem, IQQA^®IQQA: A new generation of real-time, interactive, and fully quantitative medical imaging products and intelligent cloud services, covering the entire cycle of diagnosis and treatment management. It is effectively applied to early detection and diagnosis of various cancers (especially tumors of the liver, gallbladder, pancreas, spleen, stomach, lungs, and kidneys), precise preoperative simulation and planning, comprehensive intraoperative image-guided monitoring and real-time navigation, as well as postoperative quantitative assessment and follow-up. IQQA provides comprehensive, multi-level solutions for precision diagnosis and treatment of major diseases, particularly cancer, multidisciplinary team (MDT) collaboration, and tiered diagnosis and treatment.^®is one of the registered trademarks of EDDA Technology.

SoftBank Vision Fund is committed to accelerating the global artificial intelligence (AI) revolution by investing in industry-leading, technology-driven growth companies. Its investment portfolio spans consumer internet, enterprise services, fintech, healthcare, frontier technologies, real estate, transportation and logistics, and education. In China, SoftBank Vision Fund I and II have collectively invested in more than 21 industry-leading companies.

OrbiMed is a global leading investment firm focused on the healthcare sector, with approximately $18 billion in assets under management, including secondary market funds, private equity funds, and royalty funds. With over three decades of experience investing in the global healthcare industry, OrbiMed’s portfolio spans biopharmaceuticals, life sciences, medical devices, healthcare services, and diagnostics, covering investment stages from early-stage startups and growth-phase companies to mature enterprises and post-IPO entities. The firm’s investment team comprises more than 100 professionals worldwide with backgrounds in life sciences, medicine, finance, and law. Headquartered in New York, OrbiMed maintains offices in Hong Kong, Shanghai, San Francisco, Mumbai, and Herzliya.

3W Fund focuses on fundamental, long-term investments in the Greater China region, with a strategic emphasis on the TMT, biopharmaceuticals and medical devices, new energy and advanced materials, and consumer sectors, aiming for steady long-term capital appreciation. Since its inception, 3W Fund has cultivated an investment and research team with extensive expertise in equity investment and industry knowledge. Continuously enhancing its organizational capabilities, the firm actively identifies and invests in industry leaders and high-growth emerging companies, supports corporate innovation and reform, and collaborates with entrepreneurs to achieve sustainable, long-term value investing.